{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:12:39Z","timestamp":1780614759316,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01700-7","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:11:24Z","timestamp":1745529084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Vanja","family":"Zeremski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias R.","family":"Haage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno M.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Adolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina A.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Behre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysavgi","family":"Lalayanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina P.","family":"Siakantaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"7","key":"1700_CR1","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, et al. Long-term efficacy, safety and neurotolerability of matrix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36(7):1870\u20138. https:\/\/doi.org\/10.1038\/s41375-022-01582-5.","journal-title":"Leukemia"},{"issue":"32","key":"1700_CR2","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier C, Dureau S, Taillandier L, et al. Radiotherapy or autologous Stem-Cell transplantation for primary CNS lymphoma in patients age 60 years and younger: Long-Term results of the randomized phase II PRECIS study. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(32):3692\u20138. https:\/\/doi.org\/10.1200\/JCO.22.00491.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"Supplement 2","key":"1700_CR3","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2022-171733","volume":"140","author":"G Illerhaus","year":"2022","unstructured":"Illerhaus G, Ferreri AJ, Binder M, et al. Effects on survival of Non-Myeloablative chemoimmunotherapy compared to High-Dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as consolidation therapy in patients with primary CNS Lymphoma - Results of an international randomized phase III trial (MATRix\/IELSG43). Blood. 2022;140(Supplement 2):LBA\u20133. https:\/\/doi.org\/10.1182\/blood-2022-171733.","journal-title":"Blood"},{"issue":"8","key":"1700_CR4","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/annonc\/mdy203","volume":"29","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Annals Oncology: Official J Eur Soc Med Oncol. 2018;29(8):1822\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdy203.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"23","key":"1700_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National lymphocare study. J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(23):2516\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"1700_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-023-01448-y","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Welkie RL, Torka P, et al. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. J Hematol Oncol. 2023;16(1):49. https:\/\/doi.org\/10.1186\/s13045-023-01448-y.","journal-title":"J Hematol Oncol"},{"issue":"31","key":"1700_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2217\/fon-2023-0529","volume":"19","author":"J Zhan","year":"2023","unstructured":"Zhan J, Yang S, Zhang W, et al. Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis. Future Oncol (London England). 2023;19(31):2123\u201333. https:\/\/doi.org\/10.2217\/fon-2023-0529.","journal-title":"Future Oncol (London England)"},{"key":"1700_CR8","doi-asserted-by":"publisher","unstructured":"Jang JE, Kim YR, Kim S-J et al. (2016) A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. European journal of cancer (Oxford, England: 1990) 57:127\u2013135. https:\/\/doi.org\/10.1016\/j.ejca.2016.01.016","DOI":"10.1016\/j.ejca.2016.01.016"},{"key":"1700_CR9","doi-asserted-by":"publisher","unstructured":"Ambady P, Doolittle ND, Fox CP. (2021) Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Annals of lymphoma 5:23. https:\/\/doi.org\/10.21037\/aol-21-20","DOI":"10.21037\/aol-21-20"},{"issue":"1","key":"1700_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7(1):32\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2022008525.","journal-title":"Blood Adv"},{"issue":"7","key":"1700_CR11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet S, Soussain C, Azar N, et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network. Am J Hematol. 2024;99(7):1240\u20139. https:\/\/doi.org\/10.1002\/ajh.27316.","journal-title":"Am J Hematol"},{"issue":"5","key":"1700_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.16451","volume":"189","author":"E Schorb","year":"2020","unstructured":"Schorb E, Fox CP, Kasenda B, et al. Induction therapy with the matrix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189(5):879\u201387. https:\/\/doi.org\/10.1111\/bjh.16451.","journal-title":"Br J Haematol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01700-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:11:24Z","timestamp":1745529084000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01700-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01700-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study was carried out after approval of the Medical Faculty of the Otto von Guericke University Magdeburg, Magdeburg, Germany (approval no. 18\/22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}